Drugs / Remazolam
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06205719 | Jun 2024 → May 2025 | — | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06810843 | Dec 2025 → Dec 2026 expected | lung disorder | Qianfoshan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05466279 | Jan 2021 → Oct 2023 | delirium | Fang Jun | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06731088 Comparator | Jan → Dec 2025 overdue | infectious disease with sepsis | First Affiliated Hospital of Ningbo University | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Remazolam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06731088 ↗ |
| Known as | Remazolam besylate | “Remazolam besylate is a new type of benzodiazepine sedative drug metabolized by tissue esterase.” NCT06731088 ↗ |